The idea is to keep a close watch on real-time price movements, the maximum retail price of medicines and their availability.
Currently, a lack of field inspectors does not allow the regulator to keep a tab on pharma companies or retailers flouting price caps. Recovery of overcharged amounts also becomes difficult for the regulator without a physical presence in a state.
Also Read
To deliberate on this, NPPA recently had a meeting with a few state drug controllers, including that of Delhi.
Of late, NPPA has taken some tough stands to ensure the prices of essentials, plus medicines for widely prevalent diseases, are priced reasonably. It had also taken steps to ensure no discrepancy in prices because of branding.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)